Zimmer Stock To Go Ex-dividend Tomorrow (ZMH)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for Zimmer Holdings (NYSE: ZMH) is tomorrow, June 26, 2013. Owners of shares as of market close today will be eligible for a dividend of 20 cents per share. At a price of $75.86 as of 9:30 a.m. ET, the dividend yield is 1%.

The average volume for Zimmer has been one million shares per day over the past 30 days. Zimmer has a market cap of $12.86 billion and is part of the health care sector and health services industry. Shares are up 12.9% year to date as of the close of trading on Monday.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. The company has a P/E ratio of 17.4, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Zimmer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Zimmer Ratings Report.

See our dividend calendar or top-yielding stocks list.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Zimmer Biomet's Prognosis Is Promising

Zimmer Biomet's Prognosis Is Promising

St. Jude Buying Thoratec Could Resusitate Medtech M&As

St. Jude Buying Thoratec Could Resusitate Medtech M&As

Analysts' Actions -- AT&T, Fitbit, Netflix and More

Analysts' Actions -- AT&T, Fitbit, Netflix and More

Barbarian At The Gate: Zimmer Holdings (ZMH)

Barbarian At The Gate: Zimmer Holdings (ZMH)

Deal Delay Minor Obstacle for Zimmer

Deal Delay Minor Obstacle for Zimmer